RxDoctor Payments Data

Farah Villanueva, DO

Neurology with Special Qualifications in Child Neurology · Torrance, CANPI 1144511262

Payments from drug & device makers

$3,458in general payments, 2019–2025

Across 207 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$1K
  • Novartis$598
  • Argenx US, Inc.$133
  • Pfizer$99
  • MDD US Operations, LLC$58
  • plus $268 from 9 others

What the payments were for

  • Food & beverage$3,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,458 in reported general payments places this provider in the 55th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California

Medicare billing

Part B allowed, 2024
$130,296
Medicare patients
380
Services billed
4,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$161,800
Glatiramer Acetate11$31,141
Emgality PenGalcanezumab-Gnlm37$28,571
UbrelvyUbrogepant16$16,437
Oxtellar XrOxcarbazepine11$10,317
Lacosamide13$10,073
Rasagiline Mesylate28$7,285
EliquisApixaban12$7,008
Levetiracetam152$6,645
Rivastigmine18$4,698
Quetiapine Fumarate116$4,418
RytaryCarbidopa/Levodopa14$4,360
Entacapone18$4,145
Memantine Hcl97$4,091
Donepezil Hcl304$4,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$26$161,80024 claims
AbbVieUbrelvy$1,155$16,43716 claims
PfizerEliquis$99$7,00812 claims
Lilly USA, LLCOlanzapine$48$23018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 216 neurology with special qualifications in child neurology providers in California.

Other neurology with special qualifications in child neurology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →